Nabriva Therapeutics AG 4
4 · Nabriva Therapeutics AG · Filed Jun 19, 2017
Insider Transaction Report
Form 4
Talbot George Harrison
Director
Transactions
- Sale
Common Shares
2017-06-16$93.50/sh−24$2,244→ 3,225 total - Sale
Common Shares
2017-06-19$91.00/sh−46$4,186→ 3,179 total - Sale
Common Shares
2017-06-15$94.10/sh−100$9,410→ 3,249 total
Footnotes (4)
- [F1]The common shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents one tenth (1/10) of a common share of Nabriva Therapeutics AG. The reporting person may hold both common shares and ADSs representing common shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of common shares.
- [F2]The price of $94.10 per common share was derived from the sale price on June 15, 2017, of $9.41 per ADS, multiplied by ten.
- [F3]The price of $93.50 per common share was derived from the sale price on June 16, 2017, of $9.35 per ADS, multiplied by ten.
- [F4]The price of $91.00 per common share was derived from the sale price on June 19, 2017, of $9.10 per ADS, multiplied by ten.